Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02348593 · ClinicalTrials.gov registry record · Phase 3
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 239
- Enrollment target
NCT02348593 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 239 participants.
The verdict
NCT02348593, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 239 participants
- Enrollment target
Study Summary
This trial is a 12-week, randomized, double-blind, placebo controlled, multicenter, 4-treatment parallel group study of the safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with narcolepsy.
Interventions
- DRUG Placebo oral tablet
- DRUG JZP-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02348593
The ClinicalTrials.gov registry entry for NCT02348593 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT02348593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02348593 about?
NCT02348593 is a clinical study titled ""Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"". This trial is a 12-week, randomized, double-blind, placebo controlled, multicenter, 4-treatment parallel group study of the safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with narcolepsy.
What is the current status of trial NCT02348593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 239 participants. The study started on 2015-05. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02348593?
The interventions under investigation include: Placebo oral tablet (DRUG), JZP-110 (DRUG).
Who is sponsoring clinical trial NCT02348593?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.